Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Blood Cancer Journal
|
August 23, 2014
KIT mutations in primary mediastinal B-cell lymphoma
P D Nagel, A Stenzinger, F M Feld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2021
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
C Belli, F Penault-Llorca, M Ladanyi, et al.
NPJ Precision Oncology
|
June 10, 2022
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)
E Rempel, K Kluck, S Beck, et al.
International Journal of Cancer
|
September 27, 2018
Identification of a highly lethal V3<sup>+</sup> TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma
P Christopoulos, M Kirchner, F Bozorgmehr, et al.
ESMO Open
|
September 6, 2021
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
M Kirchner, K Kluck, R Brandt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 22, 2016
Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation
I Tinhofer, V Budach, M Saki, et al.
Virchows Archiv : an International Journal of Pathology
|
January 28, 2018
Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics
B Hirsch, V Endris, S Lassmann, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 2, 2020
Risk stratification of EGFR<sup>+</sup> lung cancer diagnosed with panel-based next-generation sequencing
P Christopoulos, M Kirchner, J Roeper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
A Jahn, A Rump, T J Widmann, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Blood Cancer Journal
|
August 23, 2014
KIT mutations in primary mediastinal B-cell lymphoma
P D Nagel, A Stenzinger, F M Feld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2021
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
C Belli, F Penault-Llorca, M Ladanyi, et al.
NPJ Precision Oncology
|
June 10, 2022
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)
E Rempel, K Kluck, S Beck, et al.
International Journal of Cancer
|
September 27, 2018
Identification of a highly lethal V3<sup>+</sup> TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma
P Christopoulos, M Kirchner, F Bozorgmehr, et al.
ESMO Open
|
September 6, 2021
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
M Kirchner, K Kluck, R Brandt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 22, 2016
Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation
I Tinhofer, V Budach, M Saki, et al.
Virchows Archiv : an International Journal of Pathology
|
January 28, 2018
Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics
B Hirsch, V Endris, S Lassmann, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 2, 2020
Risk stratification of EGFR<sup>+</sup> lung cancer diagnosed with panel-based next-generation sequencing
P Christopoulos, M Kirchner, J Roeper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
A Jahn, A Rump, T J Widmann, et al.
Page
of 2